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Abstract
Inflammation is part of many neurological disorders and immune reactions may influence neuronal progenitor cells (NPCs)
contributing to the disease process. Our knowledge about the interplay between different cell types in brain inflammation
are not fully understood. It is important to know the mechanisms and factors involved in order to enhance regeneration and
brain repair. We show here that NPCs express receptors for interferon-c (IFNc), and IFNc activates the signal transducer and
activator of transcription (STAT) protein-1. IFNc reduced cell proliferation in NPCs by upregulation of the cell cycle protein
p21 as well as induced cell death of NPCs by activating caspase-3. Studies of putative factors for rescue showed that the
neuropeptide, Pituitary adenylate cyclase-activating polypeptide (PACAP) increased cell viability, the levels of p-Bad and
reduced caspase-3 activation in the NPCs. Medium from cultured microglia contained IFNc and decreased the viability of
NPCs, whilst blocking with anti-IFNc antibodies counteracted this effect. The results show that NPCs are negatively
influenced by IFNc whereas PACAP is able to modulate its action. The interplay between IFNc released from immune cells
and PACAP is of importance in brain inflammation and may affect the regeneration and recruitment of NPCs in immune
diseases. The observed effects of IFNc on NPCs deserve to be taken into account in human anti-viral therapies particularly in
children with higher rates of brain stem cell proliferation.
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Introduction
The nervous system interacts with the immune system during
inflammation that is part of many neurodegenerative diseases.
Cytokines secreted by immune cells mediate the effects of
inflammation in the brain. Increased production of cytokines is
observed in different brain disorders in experimental animals and
in humans [1]. Our knowledge about the inflammatory process in
the brain and the interplay between different cell types in
inflammation are not fully understood [1–3]. It is important to
know the different mechanisms and factors that underlie cell
reactions in brain in order to enhance regeneration and brain
repair.
NPCs are present in the developing neuroepithelium and in
neurogenic areas in the adult brain [4,5]. NPCs are self-renewing
cells that give rise to neuroblast and glial cells in the nervous
system. Different factors in the local milieu influence cell
proliferation and differentiation of NPCs [6–8]. NPCs have been
shown to react to tissue trauma as a part of the defense
mechanism. Chronic inflammation was shown to impair neuro-
genesis and negatively influence neuronal stem cells in the rodent
hippocampus [2,9]. In line with this, reduced brain inflammation
using anti-inflammatory drugs restores neurogenesis in rat
hippocampus [2] and after brain ischemia [10]. On the other
hand, glucocorticoid hormones, which are increased after stress
and immune activation, reduce neurogenesis and the proliferation
of NPCs [11]. The roles of different cytokines and their
interactions in the regulation of NPCs are so far largely unknown.
In this work, we have studied the Interferons (IFN) family of
cytokines, which are synthesized and secreted by different cells
types during inflammation and in immune reactions [12]. We
observed that NPCs express IFNc receptors (IFNcR) in vitro and in
vivo, and that stimulation with IFNc activates STAT1 signaling in
the NPCs. IFNc caused a decrease in cell viability of NPCs
accompanied by reduced cell proliferation and increased cell
death. One source of IFNc in the brain is microglial cells that
produce increasing amounts of cytokines after cell activation
[1,3,12,13]. Cultivation of NPCs with medium from microglia
decreased cell viability that was rescued by the addition of the
neuropeptide PACAP. These results reveal an important interac-
tion between NPCs and microglial cells that involves the cytokine
IFNc and neuropeptide PACAP and which is probably of
importance in brain inflammation and disease.
Results
NPCs express receptors for IFNc
In the brain, astrocytes and neurons have been shown to express
IFNcR [12,14]. Immunostaining of embryonic NPCs cultured as
neurospheres and colabelled with the marker nestin also expressed
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IFNc receptor-2 (IFNcR2, Fig. 1A). Labeling with BrdU showed
that the IFNcR2 positive cells actively divide in the cultures
(Fig. 1a). Semiquantitative PCR confirmed the expression of the
IFNcR-2 in the NPCs (Fig. 1B). IFNcR2 was also observed with
immunoblotting of NPCs and the receptors were present in
developing neuroepithelium containing nestin positive NPCs
(Fig. 1C).
IFNc decreases viability of NPCs and affects cell
proliferation
Treatment of NPCs with 100 ng/ml IFNc induced the rapid
phosphorylation of STAT1 (Fig. 2A), with translocation of the
protein into the nucleus (Fig. 2B). IFNc also decreased the viability
of NPCs (Fig. 2C). Dose response curve showed that the half-
maximum effect of IFNc was about 3 ng/ml (Fig. 2D). Immuno-
staining confirmed that the number of nestin positive NPCs
decreased after IFNc treatment (Fig. 2E), and IFNc reduced the
number of secondary neurospheres formed in the cultures (Fig. 2F).
A decrease in cell viability may be due to reduced cell
proliferation and/or enhanced cell death. Data showed that IFNc
significantly reduced the number of BrdU labeled NPCs (Fig. 3A).
Similar results were obtained using antibodies against the
proliferation antigen Ki67 (Fig. 3B). These results show that IFNc
decreases cell proliferation of NPCs that contributes to the reduced
number of NPCs after IFNc.
Previous studies have shown that cell cycle regulators, including
p53 and cyclinD1 influence cell proliferation in NPCs [11,15,16].
The addition of IFNc did not influence cyclinD1 nor p53 levels, as
shown by immunoblotting (Fig. 3C). However, IFNc increased the
levels of p21 protein in the NPCs (Fig. 3C), which was also
Figure 1. Neural progenitor cells express IFNc receptors. NPCs were prepared from embryonic, E17 old rat brain and cultured as described in
Methods. (A) Upper panel. Immunostaining using antibodies against the IFNcR2 receptor (green fluorescence) and against nestin (red fluorescence)
as a marker for NPCs. Control without primary antibody showed no staining. Lower panel. BrdU labeling was done as described in Methods. Note
expression of IFNcR2 in dividing NPCs. Scale bar, 10 mm. (B) Immunoblot shows the presence of IFNcR2. b-actin was used as control. (C) Sections
from E17 rats were double-stained using antibodies against nestin and IFNcR2. Note coexpression in cells in neuroepithelium. Scale bar, 90 mm.
doi:10.1371/journal.pone.0011091.g001
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observed using RT-PCR (Fig. 3D). To study p21 more closely, we
employed silencing RNA (siRNA) against p21. Treatment with
p21 siRNA reduced the effect of IFNc on cell proliferation as
shown here by analyzing phospho-vimentin (p-vimentin) levels and
the number of BrdU labeled cells (Fig. 3E) [17]. In contrast,
lowering p53 levels by siRNA did not influence the decrease in cell
proliferation caused by IFNc (Fig. 3F). This shows that p53 is
indispensable for the IFNc-induced decrease in cell proliferation in
the NPCs. In line with this, we observed that the number of p53
deficient mouse embryonic fibroblasts was also reduced by IFNc,
showing a p53 independent action for IFNc to regulate cell
viability (Fig. 3G).
IFNc induces cell death and activates caspase-3 in NPCs
Cell cycle analyses of NPCs revealed that IFNc decreased the S-
phase together with an increase in the sub-G0 phase (data not
shown). We therefore studied whether enhanced cell death can
contribute to reduced cell viability of NPCs observed with IFNc.
Staining of cells using propidium iodide or Terminal deoxynu-
cleotidyl transferase-mediated biotinylated UTP nick end labeling
(TUNEL) to analyze DNA fragmentation showed that IFNc
increased cell death of NPCs (Fig. 4. A, B). To study the
mechanism involved, we analyzed caspase-3, a key caspase
involved in cell death. Immunoblotting showed that IFNc caused
cleavage of caspase-3 and its downstream substrate, poly-ADP
ribose polymerase (PARP) (Fig. 4C). Addition of BAF, a large
spectrum caspase inhibitor, reduced cell death induced by IFNc
(Fig. 4D). Immunostaining showed that cytochrome-c was present
in the cytoplasm of IFNc-treated NPCs but not in control cells
(data not shown). The release of cytochrome-c is controlled by the
action of Bcl-2 family proteins on mitochondria [18]. As shown
below, IFNc increased the levels of the pro-apoptotic protein
PUMA in NPCs.
The neuropeptide PACAP increases cell viability of IFNc-
treated NPCs
To search for putative rescue factors to counteract the negative
effects of IFNc we incubated NPCs in the presence of various
Figure 2. IFNc activates STAT signaling and decreases cell viability of NPCs. NPCs were treated with 100 ng/ml IFNc for different times and
analyzed as described in Methods. *p,0.05 and **p,0.001 comparing IFNc treated vs. controls. (A) Immunoblot shows increased levels of phospho-
STAT1 (p-Stat1) after 0.5 h. (B) Immunostaining showed the presence of p-Stat1 in the nucleus after 2 h treatment. Scale bar, 10 mm. (C) Cell viability
was determined by the MTT assay as described in Methods. Values are means 6SD, n = 4. (D) Dose response curve. Cells were treated for 48 h and
cell viability determined. Values are means 6SD, n = 4. (E) Cells were treated for 48 h and the number of nestin positive NPCs was analyzed. Values
are means 6SD, n = 4. (F) Neurospheres were dissociated and about 5000 cells per well were incubated for 3days in absence or presence of 100 ng/
ml IFNc. The number of secondary neurospheres formed was counted. Values are means 6SD, n = 4.
doi:10.1371/journal.pone.0011091.g002
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Figure 3. IFNc decreases cell proliferation of NPCs via p21. NPCs were treated with 100 ng/ml IFNc for 2 days. *p,0.05 and ***p,0.001
comparing IFNc treated vs. controls. (A) 10 mM BrdU was added to the cultures to label DNA and immunostaining done using anti-BrdU antibodies.
Values are means6SD, n = 4. (B) Immunostaining using antibody against Ki67. Values are means6SD, n = 4. (C) Immunoblots. Cells were treated for
24 h. Note upregulation of p21 with no change in cyclinD1. Immunoprecipitation (IP) of p53 was performed prior to blotting. (D) RT-PCR for p21 was
done as described. Typical experiment is shown and was repeated 3 times. (E) NPCs were treated with siRNA against p21 for 2 days followed by IFNc
for 24 h Upper panel, Immunoblots showing p-vimentin as a measure of cell proliferation. IFNc decreased p-vimentin in control but not in p21-siRNA
INF-c Reduces NPC Viability
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proteins and cytokines with receptors on NPCs. The results
showed that none of the growth factors examined, including brain-
derived neurotrophic factor (BDNF) was able to increase viability
of NPCs compromised by IFNc (Fig. 5A). In addition, IFNa or
IFNb did not counteract the effect of IFNc (Fig. 5A). Cytokines,
including IL-10 and TGFb, which have an immune-suppressive
function, had no protective effect in this system, nor did anti-
inflammatory drugs including indomethacin (Fig. 5B,C). Analyses
of neuropeptides that are endogenous factors in brain tissue
revealed that PACAP [19] increased cell viability (Fig. 5D).
PACAP efficiently counteracted the effect of IFNc at nM
concentrations that is known to activate the high affinity PACAP
receptor, PAC1 (Fig. 5E).
Mechanisms of PACAP action for cell rescue
IFNc signaling is tightly controlled at different levels, including
dephosphorylation of p-STAT1 and the induction of the
suppressor of cytokine signaling (SOCS) proteins [20]. PACAP
did not influence the level of IFNc receptors (data not shown), nor
the phoshorylation of STAT1 induced by IFNc (Fig. 6A). The
level of SOCS1 increased in the NPCs by IFNc, whereas those of
SOCS3 did not (Fig. 6B).
Studies of cell death regulators showed that PACAP did not
influence the anti-apoptotic protein Bcl-X in the NPCs, but
decreased the level of the pro-apoptotic protein PUMA that was
upregulated by IFNc (Fig. 6C). PACAP also increased the
phosphorylation of Bad at serine-112 (Fig. 6D), which leads to
inactivation of this pro-apoptotic protein [21].
To study the signaling pathways underlying the effect of
PACAP, we employed inhibitors against protein kinase A (PKA)
and protein kinase C (PKC). The PKC inhibitor, Go¨6976,
reduced the beneficial effect of PACAP on cell viability, whilst the
PKA inhibitor, H89 did not (Fig. 6E). These results show that the
effect of PACAP in increasing cell viability in NPCs involves PKC.
PACAP has previously been shown to enhance cell proliferation
in adult neural stem cells [22,23]. We observed that PACAP
Figure 4. IFNc induces cell death in NPCs via caspase-3. NPCs were treated with 100 ng/ml IFNc for different time periods and analyzed
further. *p,0.05 and **p,0.01 comparing IFNc treated vs. controls. (A) Number of propidium iodine positive cells was determined by counting.
Values are means6SD, n = 4. (B) Number of TUNEL positive cells. Values are means +SD, n = 3. Inset show typical labeling in control and IFNc treated
cells. (C) Immunoblot. Note increased active caspase-3 (17 kDa band) and cleaved PARP (89 kDa). Typical blot is shown and was repeated three times.
(D) Effect of caspase inhibitor. NPCs were incubated for 24 h with 50 mM BAF in conjunction with IFNc. Values are means +SD, n = 3.
doi:10.1371/journal.pone.0011091.g004
treated cells. Lower panel, BrdU labeling was decreased in control but not in p21-siRNA treated cells. (F) NPCs were treated with siRNA against p53
followed by IFNc as above. IFNc reduces cell proliferation in p53-siRNA treated cells. (G) p53 gene deleted mouse embryonic fibroblasts were treated
with 10–100 ng/ml IFNc for 2 days and cell viability determined as described in Methods.
doi:10.1371/journal.pone.0011091.g003
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increased proliferation of control NPCs, but the effect was not
statistically significant in NPCs treated with IFNc (Fig. 6F).
Therefore in this situation PACAP acts mainly as a survival
promoting peptide reducing the inhibitory effect of IFNc.
Microglia affect NPCs via IFNc
In the brain, microglial cells represent a defense system that
takes part in inflammation and in immune reactions. Activation of
microglial cells is followed by increased production of various
cytokines. We observed that activation of rat microglial cells by
lipopolysaccaride (LPS) led to increased levels of IFNc in the
culture medium as shown by ELISA (Fig. 7A). Addition of the
LPS-conditioned medium to NPCs reduced cell viability by up to
40% compared with media from control cells (Fig. 7B left panels).
Supplementation of the conditioned media with 50 nM PACAP
counteracted the decrease in viability of NPCs (Fig. 7B right
panels). LPS itself had no effect on NPCs viability excluding
nonspecific effects of the compound (Fig. 7C). Incubation of the
microglia-derived medium with anti-IFNc blocking antibodies
largely reduced its negative effect on cell viability (Fig. 7D). These
results show that microglia produce IFNc and that PACAP is able
to counteract the decrease in cell viability observed with the
microglia-conditioned medium.
Discussion
The present results show that IFNc influences NPCs in two
ways by decreasing cell proliferation and by increasing cell death.
IFNc affected cell proliferation by inducing expression of p21, and
cell death by influencing various Bcl-2 family proteins and caspase-
Figure 5. Effects of different factors in IFNc-treated NPCs. NPCs were untreated (white bars) or treated for 24 h with various factors alone
(black bars) or together with 100 ng/ml IFNc (grey bars). Cell viability was assayed by MTT. Values are means6SD, n= 4. *p,0.05 for IFNc treated vs.
controls. (A) BDNF and GDNF were used at 50 ng/ml and IFNs at 100 ng/ml. Values are means6SD, n= 4. No increase in viability by the factors. (B)
Different cytokines were used at 50 ng/ml. No increase in viability by the factors. (C) 100 ng/ml Indometacin (Indo), 100 ng/ml Minocyclin (Mino), and
1 mM Forskolin (Forsk) were used. No increase in viability by the compounds. (D) 100 ng/ml PACAP increased cell viability reduced by IFNc. (E) Dose
response curve for PACAP. **P,0.01 for PACAP+IFNc vs. IFNc.
doi:10.1371/journal.pone.0011091.g005
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3 activation. Previous studies have shown that cell cycle regulators
including p53 and cyclinD1 are important for cell proliferation of
NPCs [11,15,16], but we observed no significant change in these
proteins in IFNc-treated NPCs. In addition, IFNc reduced cell
proliferation also in p53 deficient fibroblasts and in NPCs after
downregulation of p53 by siRNA. p21 is a downstream target for
p53 but the protein may be regulated also by other factors. We
observed that IFNc increased the expression of p21 in NPCs,
leading to a decrease in cell proliferation. In line with this, IFNc
has been shown to regulate p21 in human breast cancer cells via
transcriptional upregulation [24].
IFNs are divided into two major classes: type-1 IFNs, with the
structurally related IFNa, IFNb, and type-2 IFN, with IFNc [12].
The IFNs bind to specific IFN receptors on target cells and
activate gene transcription through the STAT and Janus tyrosine
kinase signaling pathway [25]. IFN receptors are predominantly
expressed by the immune cells, but in the brain astrocytes and
neurons also show expression [12,14]. Administration of IFNs
including IFNc has been shown to modulate neuronal activity and
to alter behavior in experimental animals [12]. The exact roles of
IFNc in brain physiology and its cellular targets are, however, not
fully understood.
In the present study, we observed a high abundance of IFNc
receptors in neural precursor cells in neuroepithelium during rat
embryonic development and in NPCs cells in culture. IFNc
activated STAT-1 signaling and the nuclear translocation of the
protein. STAT-1 in turn activates transcription of downstream
genes including those affecting inflammation, cell signaling and
cell survival [20,25]. IFNc was found to increase levels of the BH-3
only protein PUMA in the NPCs, which can induce the
mitochondrial pathway of cell death [18,21,26]. In IFNc treated
cells cytochrome-c was released into the cytoplasm with activation
of caspase-3, the cleavage of PARP and with increased DNA
fragmentation. Incubation with the caspase-inhibitor, BAF
Figure 6. Effect of PACAP on NPCs. NPCs were treated for 24 h with 100 ng/ml IFNc alone or in conjunction with 100 ng/ml PACAP. (A)
Immunoblot. Cells were treated for 2 h. PACAP did not influence levels of p-Stat1 induced by IFNc. (B) RT-PCR. SOCS-1 and –3 levels are not
influenced by PACAP. IFNc upregulated SOCS1. (C) Immunoblots. IFNc increased whilst PACAP decreased levels of PUMA. PACAP also decreased
active caspase-3 (17 kDa band). Typical blot is shown and was repeated three times. (D) Immunoblots. PACAP increased levels of p-Bad. Typical blot
is shown and was repeated three times. (E) Effects of the kinase inhibitors on cell viability measured by MTT. 1 mM Go¨6976 reduced the beneficial
effect of PACAP whereas 10 mM H89 had no effect. Values are means 6SD, n= 4. *** p,0.005 for IFNc vs. controls, and *p,0.0 for IFNc+PACAP vs.
IFNc, and for GO¨+ IFNc+PACAP vs. IFNc+PACAP. (F) BrdU labeling. PACAP increases cell proliferation significantly in control but not in IFNc treated
cells. Values are means6SD, n = 4. * p,0.05 for PACAP vs control cells, n = 3.
doi:10.1371/journal.pone.0011091.g006
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protected NPCs against cell death induced by IFNc. These results
show that IFNc influences cell death in NPCs by influencing a
subset of death-regulating proteins including PUMA with the
activation of caspase-3.
The observed decrease in cell viability induced by IFNc may
negatively influence the survival and recruitment of NPCs after
brain injury or in different diseases. We therefore studied a variety
of growth factors and cytokines with described receptors on NPCs
for their ability to counteract the effects of IFNc. Of the many
factors examined, the neuropeptide PACAP had the largest effect
in increasing cell viability. PACAP is a member of the vasoactive
intestinal peptide/secretin/glucagon peptide family [19] and is
present in embryonic and adult brain tissue [27–32]. PACAP
binds to its high-affinity PAC1 receptor that is expressed by
different target cells [33,34], including NPCs [27]. Previous studies
have shown that PACAP increases proliferation/survival of adult
neural stem cells [2,23,35]. PACAP also increases neuronal
survival in different systems [31,36], however, this action may
involve other growth factors, such as insulin growth factor-1 [33]
and interleukin-6 (IL-6) [37]. We observed that neither IL-6 nor
the other neurotrophic factors studied counteract the IFNc-
induced loss of cell viability. In contrast, PACAP at low
concentrations exerted a robust protection against cell degenera-
tion of NPCs induced by IFNc, The enhanced cell viability
induced by PACAP was accompanied by increases in p-Bad that
can inhibit the mitochondrial mediated cell death [21]. In line
with this, the activation of caspase-3 by IFNc was reduced in
PACAP-treated NPCs. This data suggests that alterations in
expression and phosphorylation of Bcl-2 family proteins may
underlie the increase in NPC viability induced by PACAP.
Inhibitor studies further showed that increased cell viability by
PACAP was mainly mediated by an activation of PKC in NPCs.
Molecular cloning has revealed the existence of six different splice
variants of the PAC1 receptors, which can activate cell signaling of
PACAP either through PKC or PKA [33]. These splice variants
are also present in neural stem cells and mediate various cellular
responses to PACAP [22,23,35].
Studying the possible crosstalk between PACAP and IFNc, we
observed that PACAP did not influence STAT1 signaling nor did
PACAP affect the IFNc receptor levels in NPCs (Fig. 6). IFNc
receptor signaling is a complex process controlled by several
factors including the SOCS proteins [20]. As studied here, SOCS-
1 and -3 are expressed by NPCs but these proteins were not
altered by PACAP. Although the signaling cascades induced by
IFNc and PACAP do not directly overlap, some genes including
the Bcl-2 family proteins are differentially regulated by these two
factors. Future studies using gene profiling will reveal which other
proteins are regulated by PACAP and by IFNc in the NPCs.
Apart from cell survival, PACAP may increase viability of IFNc-
treated NPCs by enhancing cell division [22]. We observed a slight
increase in cell proliferation by PACAP after IFNc treatment but
this was not statistically significant as shown using BrdU labeling
(Fig. 6G). We therefore conclude that the major effect of PACAP
on IFNc-treated NPCs was to promote cell survival by inhibition
of caspase-3 activation and increasing p-Bad levels.
Brain tissue is usually though as being protected from
immunological reactions in the body by the presence of the blood
brain barrier. The immune and nervous systems interact with each
Figure 7. Microglia-conditioned medium decreases NPC via-
bility. Microglial cells from rat brain were cultured and treated as
described in Methods. (A) Activation of microglia using 500 ng/ml LPS.
IFNc was studied using ELISA as described in Methods. Positive and
negative controls were from the Quantikine kit. ***p,0.001 vs. controls,
n = 4. (B) Left panels, 30 ml medium from control microglia (C) or 1–
30 ml conditioned-medium (CM) from LPS-treated microglia was added
to 100 ml NPCs cultures. Values are means 6SD n=3. *p,0.02 and
**p,0.05 for 10–30 ml CM vs. C Right panels, 50 ng/ml PACAP was
added to half the cultures and cell viability assayed after 24 h using
MTT. *p,0.05 for 30 ml PACAP+CM vs. C. (C) 10–500 ng/ml LPS was
added directly to NPCs for 24 and cell viability studied. No change with
LPS alone. (D) NPCs were incubated with 30 ml control medium (C) or
with 15 (CM15) or 30 ml (CM30) medium from LPS-treated microglia in
absence or presence of 0.25 mg/ml blocking anti-IFNc antibodies (IFN-
Ab). Values are means 6SD n= 3. *p,0.02 for IFN-Ab vs. CM-treated
cultures.
doi:10.1371/journal.pone.0011091.g007
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other in conditions characterized by increased leakage of the blood
brain barrier that occurs after an immune challenge or in brain
inflammation. The activation of immune cells occurs in various
human brain disorders and neurodegenerative diseases [1]. The
levels of IFNc increase in brain in different diseases, such as
multiple sclerosis and encephalitis and following immune reac-
tions. IFNc may be produced by invading immune cells or by
resident microglial cells that are activated during the inflammatory
process. Microglia have recently been shown to interact with
neural stem cells and these cells may mediate both positive [38,39]
and negative effects on NPCs (this study). NPCs in turn exert
potent anti-inflammatory actions in vivo [40,41]. The final outcome
of interaction between NPCs and inflammatory cells probably
depends on the amount of secreted cytokines at each moment. We
observed that LPS-activated microglia cells produce IFNc into the
culture medium and this negatively affected the NPCs. Experi-
ments using blocking antibodies against IFNc showed that a part
of the activity in the medium is due to IFNc, although other
factors cannot be excluded. In line with our data, it was recently
reported that the addition of IFNc inhibited neurosphere
formation in adult murine NPCs [42]. Previous studies have
shown that PACAP may have potent anti-inflammatory function
in regulating the production of pro-inflammatory mediators [43].
This has recently been confirmed in PACAP gene deficient mice
that showed an increased expression of pro-inflammatory
cytokines including IFNc [44]. We show here that PACAP
directly acts on NPCs to counteract the effects of IFNc. PACAP is
able to pass the blood-brain barrier [45]. PACAP may therefore be
useful in treatment of brain inflammation and to enhance
recruitment of endogenous NPCs after injury and conditions with
high IFNc production. Due to its robust cell survival effects on
NPCs PACAP may also be considered as an adjuvant treatment in
different NPC transplantation studies.
Materials and Methods
Animals
Wistar rats were obtained from Harlan (Horst, The Nether-
lands). All experiments were approved by the local ethical
committee and performed in accordance with the European
Communities Council Directive (86/609/EEC).
Cell culture
NPCs were prepared from embryonic (E) 17-old rat brains as
described [11,46,47]. Cells were cultured in medium containing
20 ng/ml epidermal growth factor (EGF) (PeproTech, Rocky Hill,
NJ), and B27 supplement in DMEM/F-12 (Gibco, Invitrogen
Carlsbad, CA, USA). Neurospheres were grown for 5 days, gently
dissociated, and collected by centrifugation for 5 min at 1500 rpm.
The cells were resuspended into appropriate volume of medium
containing EGF, different IFNs (PeproTech), PACAP-38 (Ba-
chem, Bubendorf, Switzerland) and growth factors and cytokines
added as indicated. These included BDNF (PeproTech) G-CSF;
GM-CSF, IL-6, IL-10, CNTF (Sigma, St. Louis, MO, USA) that
have shown to act on NPCs. Broad range caspase inhibitor boc-
aspartyl (Ome)-fluoromethylketone (BAF) was from Calbiochem
(San Diego, CA, USA) and the compounds, indomethacin,
minocyclin and forskolin and kinase inhibitors, H89 and
Go¨6976 were all from Sigma.
Microglial cells were prepared from newborn rat brain
essentially as described [13]. and kept in culture for up to three
weeks in Dulbecco’s modified Eagle’s medium (DMEM)/F12
medium (Gibco) supplemented with 10% fetal bovine serum, and
penicillin/streptomycin at 37uC in 5% CO2 atmosphere. Cells
were stimulated for 24 h using bacterial lipopolysaccharides (LPS,
Sigma) and conditioned medium (CM) collected and the amount
of IFNc analyzed using ELISA and the rat Quantikine assay
(R&D Systems, Minneapolis, USA). Blocking anti-IFNc antibodies
was from R&D Systems. Unstimulated CM was used as control.
CM from microglial cells was added to cultures of NPCs and cell
viability determined as below. p53 gene deleted mouse embryonic
fibroblasts (kind gift of M Laiho) were cultured in DMEM/10%
fetal bovine serum and stimulated with 100 ng/ml mouse IFNc
(PeproTech).
NSC viability, cell death and proliferation assays
NSCs were cultured in 96-well cell culture dishes (70,000 cells
per well; Costar 3599; Corning) in the presence of 20 ng/ml EGF
and different concentrations of IFNc and PACAP. To estimate the
viability of cells, we used the MTT [3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (Sigma) assay as described
previously [11,46,47]. For TUNEL staining of DNA breaks the
In Situ Cell Death Detection Kit (Roche, Basel. Switzerland) was
used as described [11,48,49]. BrdU (Sigma) labeling and
immunostaining using the Ki67 antibody (1:300; BD Biosciences,
Franklin Lakes, NJ, USA) were performed to estimate the number
of proliferating cells [11,49]. Cell cycle analyses were done using
flow cytometry using a FACS calibur flow cytometer [50]. To
estimate the capacity for self-renewal an equal number of NPCs
(5000 cells) were incubated for 3 days in the absence and presence
of 100 ng/ml IFNc and the number of neurospheres counted
[11,47].
Immunochemistry
NPCs plated in 24-well culture dishes coated with poly-DL-
ornithine (50 mg/ml), fixed for 20 min using 4% paraformalde-
hyde, and blocked for 1 h using 3% BSA in PBS/0.1% Triton X-
100. The following primary antibodies were added overnight at
4uC: IFNcR2 (diluted 1:1500; Abcam, Cambridge, UK), cyto-
chrome-c (1:200 BD Bioscience), phospho-STAT1 (1:1000; Cell
Signaling Technology, Inc., Danvers, MA, USA), and nestin
(1:1000; R&D Systems). Secondary Alexa 488 and Alexa 594
flurosecent antibodies (1:500; Invitrogen) were added for 1 h in
PBS in 1% BSA and 0.1% Triton X-100. The number of
immunoreactive cells in each well was counted using fluorescent
microscopy in four independent fields.
For staining of neuroepithelium, 15 mm sections from E17 old
rats were cut using a Leitz (Wetzlar, Germany) microtome and
placed on SuperFrost Plus glass slides [11]. Anti-IFNcR2 (diluted
1:500) or anti-nestin (1:100) antibodies were added overnight
together with followed by washing with PBS. Appropriate
secondary antibodies were added for 1 h and sections were
washed and mounted with gel mounting medium (Gel Mount;
Sigma).
Immunoblots
Cells were lysed in a buffer containing 50 mM Tris-HCl
(Ph 7.4), 1% NP-40, 0.25% natriumdeoxycholate, 150 mM NaCl,
1 mM EDTA, and protease inhibitors (Roche) [11,48]. In some
experiments phosStop solution (Roche) was added to inhibit
phosphatases. 40–80 mg total protein were separated using SDS–
PAGE, transferred to nitrocellulose membranes (Hybond-C Extra,
Amersham), blocked for 1 h in 5% skim milk, and incubated
overnight at 4uC with primary antibody in blocking buffer.
Antibodies used were: cyclin D1 (1:750) and Bax (1:250) from
Santa-Cruz (CA, USA), STAT1 (1:400), p-STAT1 (1:500);
caspase-3 (1:1000), cleaved caspase-3 (1:1000); PARP (1:2000),
p53 (1:1000), Bad (1:1000), p-Bad (1:500; phospho-Ser112), and
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Puma (1:1000) all from Cell Signaling, Bcl2 (1:400) and Bcl-xL (1;
1000) from BD Bioscience, IFNcR-2 (1:3000; Abcam), p21 (1:200;
Millipore, MA, USA), p-vimentin (1:2000; phospho-Ser55 Assay
Designs, Ann Arbor, MI, USA), and b-actin (1:2000, Sigma).
Appropriate peroxidase-conjugated antibodies (1:2500, Jackson
Immunoresearch, Newmarket, Suffolk, UK) were added for 1 h
and detection was performed using SuperSignal West Pico
Substrate (Pierce). Quantification was performed using GelDoc
(BioRad).
Silencing RNA
100 nM siRNA construct against p53 and against p21
(Dharmacon, Lafayette, CO, USA) was tranfected using the
Amaxa Nucleofector system and 56106 NPCs [48,49]. Equal
number of control and treated cells were incubated for 48 h
followed by 100 ng/ml IFNc for additional 24 h. Efficacy of
downregulation was analyzed by immunblotting and the levels of
p-vimentin that increases during M-phase of the cell cycle [17].
RT-PCR
Total RNA was extracted from NPCs, cDNA and polymerase
chain reaction (PCR) performed as described before [11,47] using
30cycles of amplification and with following steps: 95uC for 30 s,
60uC for 30 s and 72uC for 60 s. Primers were: IFNcR1, forward
(Fw), 59-CGC CTG TAT CCC CTT TCT CCA T-39 and
Reverse (Rev), 59-CAT CTT TGT TTC CGA GTC GTT GTT
T-39; IFNcR2, Fw, 59-CGG CCG CTT GAA GGT TTT CCC
ATA C-39 and Rev, 59-GAG GCA TCC GCT GTT GTT TCG
TGA C-39;
PAC1 receptor: Fw, 59- GCT CTA TTT TGA TGA TGC AG-
39 Rev, 59-CTT GCT CAG GAT GGA CAG CT-39; p21 Fw, 59-
AGG CAG ACC AGC CTA ACA GA -39; Rev: 59- CAG CAC
TAA GGA GCC TAC CG -39; b-actin, Fw, 59-CAC ACT GTG
CCC ATC TAT GA-39 and Rev, 59-CCA TCT CTT GCT CGA
AGT CT-39
Statistics
Statistical comparisons were performed using Student’s t-test
when comparing two groups, or one-way ANOVA followed by a
Bonferroni post hoc test when comparing three or more groups.
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